Tatiana Novobrantseva is currently serving as the Chief Scientific Officer of Immuno-Oncology at Moderna. Prior to joining Moderna, Tatiana co-Founded Verseau Therapeutics and served as its Chief Scientific Officer. Previously, Tatiana consulted for multiple companies on immunological aspects of drug development across different stages and therapeutic modalities in a variety of autoimmune, cancer and rare disease indications. At her prior position as founding employee and Director of Tumor Immunology at Jounce Therapeutics, Tatiana defined research plans for several programs at the company’s inception, as well as led a portfolio of programs on (re)activating the immune system against cancer. Earlier Tatiana served as Associate Director at Alnylam Pharmaceuticals working on multiple programs including non-liver delivery of siRNA. Her industry career started at Biogen. Tatiana’s scientific accomplishments include discovering the critical role for B cells in liver fibrosis, developing mechanistic insights for multiple therapeutic programs, pushing the envelope on siRNA delivery and championing a dendritic cell cancer vaccine clinical program. Tatiana completed her Postdoctoral training at Harvard Medical School. Tatiana’s Ph.D. was performed under supervision of Dr. Klaus Rajewsky at the University of Cologne in Germany, focusing on B cell development and function. She holds a Diploma of engineer-physicist and an M.S. in molecular biology from Moscow Institute of Physics and Technology.